The controlled release profile of risedronate emulgel to inhibit relapse movement in orthodontic treatment

Tita Ratya Utari; Muhammad Fariez Kurniawan; Shylvia Muchsin Andewa

doi:10.24198/pjd.vol34no1.32628

The controlled release profile of risedronate emulgel to inhibit relapse movement in orthodontic treatment

Tita Ratya Utari, Muhammad Fariez Kurniawan, Shylvia Muchsin Andewa

Abstract

Introduction: Relapse is one of the undesirable effects of orthodontic treatment. Prevention of relapse has been carried out with the use of retainer devices. Several studies also have been carried out to prevent relapse with pharmacological agents such as bisphosphonates. One of the strongest bisphosphonates is risedronate. Systemic use of bisphosphonates can cause bisphosphonate-related necrosis of the jaw (BRONJ). Systemic effects can be minimised by topical preparations locally, where the virgin coconut oil (VCO) emulgel is one of the topical preparations which controls the release of drugs. This study aims to analyse the release profile of risedronate emulgel as a material to inhibit relapse movement. Methods: This research was conducted in an experimental laboratory. Group 1 was emulgel without bisphosphonate risedronate with virgin coconut oil (VCO), Group 2 was VCO emulgel with bisphosphonates risedronate, and Group 3 was a pure bisphosphonate risedronate solution. Each group weighing 100 mg was placed in 10 ml PBS, and the release test was conducted with UV/VIS Spectrophotometer wavelength λ 262 nm at intervals of 1, 2, 4, 8, 24, 48, and 96 hours with three replications at each group. Results: Grup 2 yielded a controlled drug release of risedronate until 96 hours, while a pure solution of risedronate resulted in an uncontrolled drug release of risedronate, which was released entirely in 4 hours. Conclusion: Risedronate emulgel with VCO had a controlled drug release compared to pure bisphosphonate solution to potentially be applied topically to inhibit relapse movement.

Keywords

relapse; emulgel; bisphosphonate risedronate; controlled release

Full Text:

PDF

References

Kandi DD, Gulve N, Patani S, Nehete A, Aphale H, More P, Raunka R. The Prevalence of Malocclusion in Dental Students and Reasons for Avoiding Orthodontic Treatment. Int J Oral Health Med Res 2016; 2(5): 40-2.

Kumar P, Londhe SM, Kotwal A, Mitra R. Prevalence of Malocclusion and Orthodontic Treatment Need in Schoolchildren-An Epidemiological Study. Medical Journal Armed Forces India. 2013; 69(4): 369-74. DOI: 10.1016/j.mjafi.2012.02.003.

Pangrazio-Kulbersh V, Kang HK, Dhawan A, Al-Qawasmi R, Pacheco RR. Comparison of early treatment outcomes rendered in three different types of malocclusions. Angle Orthod. 2018; 88(3): 253-8. DOI: 10.2319/091417-618.1.

Vieira GM, Falcao DP, De Queiroz SBF, De Lima VN, De Azevedo RB, Tiziane V, et al. A novel analysis via Micro-CT imaging indicates that chemically modified tetracycline-3 (CMT-3) inhibits tooth relapse after orthodontic movement: A pilot experimental study. Int J Dent. 2019; 2019: 1-8. DOI: 10.1155/2019/3524207

Abdulraheem S, Schütz-Fransson U, Bjerklin K. Teeth movement 12 years after orthodontic treatment with and without retainer: relapse or usual changes? Eur J Orthod. 2020; 42(1): 52-59. DOI: 10.1093/ejo/cjz020.

Han G, Chen Y, Hou J, Liu C, Chen C, Zhuang J, Meng W. Effects of simvastatin on relapse and remodeling of periodontal tissues after tooth movement in rats. Am J Orthod Dentofacial Orthop. 2012; 138(5): 550.e1-7; discussion 550-1. DOI: 10.1016/j.ajodo.2010.04.026.

Johnston CD, Littlewood SJ. Retention in orthodontics. Br Dent J. 2015; 218(3): 119-22. DOI: 10.1038/sj.bdj.2015.47.

Zhao N, Lin J, Kanzaki H, Ni J, Chen Z, Liang W, Liu Y. Local osteoprotegerin gene transfer inhibits relapse of orthodontic tooth movement. Am J Orthod Dentofacial Orthop. 2012; 141(1): 30-40. DOI: 10.1016/j.ajodo.2011.06.035.

Esfahani N. E, Sadeghian S, Razavi M, Minaiyan M, Afsari E. The Effects of Simvastatin on Bone Remodeling, Tooth Movement and Root Resorption in Orthodontic Treatments. Biomed Pharmacol J. 2013;6(2)

Krishnan S, Pandian S, Kumar S A. Effect of bisphosphonates on orthodontic tooth movement-an update. J Clin Diagn Res. 2015; 9(4): ZE01-5. DOI: 10.7860/JCDR/2015/11162.5769.

Venkataramana V, Chidambaram S, Reddy BV, Goud EV, Arafath M, Krishnan6 S. Impact of Bisphosphonate on Orthodontic tooth movement and osteoclastic count: An Animal Study. J Int Oral Health. 2014; 6(2): 1-8.

Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E. Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience. Int J Dent. 2016; 2016: 1801676. DOI: 10.1155/2016/1801676.

Abdik H, Avşar Abdik E, Demirci S, Doğan A, Turan D, Şahin F. The effects of bisphosphonates on osteonecrosis of jaw bone: A stem cell perspective. Mol Biol Rep. 2019; 46(1): 763-776. DOI: 10.1007/S11033-018-4532-X

Kim S, Seiryu M, Okada S, Kuroishi T, Takano-Yamamoto T, Sugawara S, Endo Y. Analgesic effects of the non-nitrogen-containing bisphosphonates etidronate and clodronate, independent of anti-resorptive effects on bone. Eur J Pharmacol. 2013 Jan 15;699(1-3):14-22. DOI: 10.1016/j.ejphar.2012.11.031.

Nuti R. Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis. Clin Cases Miner Bone Metab. 2014; 11(3): 208-14.

Krishnan S, Pandian S, Kumar S A. Effect of bisphosphonates on orthodontic tooth movement-an update. J Clin Diagn Res. 2015; 9(4): ZE01-5. DOI: 10.7860/JCDR/2015/11162.5769.

George EL, Lin YL, Saunders MM. Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. Bone Rep. 2018; 8: 104-9. DOI: 10.1016/j.bonr.2018.03.003.

Choudhury H, Gorain B, Chatterjee B, Mandal UK, Sengupta P, Tekade RK. Pharmacokinetic and pharmacodynamic features of nanoemulsion following oral, intravenous, topical and nasal route. Curr Pharm Des. 2017; 23(17): 2504-2531. DOI: 10.2174/1381612822666161201143600

Gayatri PA, Sahlan M, Pratami DK, Widayati R. Stability of Zoledronate Gel Emulsion in Virgin Coconut Oil. Int J App Pharm. 2019; 11(6) 201–6. DOI: 10.22159/ijap.2019.v11s1.18204

Rachmawati MW, Yoshida N, Tsuboi H, Kimura K, Yoshida N, Tsuboi H, et al. Investigation of antibiotic use at a Dental Teaching Hospital in Yogyakarta, Indonesia: A review from guidelines. Pharmacol Pharm. 2014; 5(5): 524-31. DOI: 10.4236/PP.2014.55062

Utari TR, Ana ID, Pudyani PS, Asmara W. The intrasulcular application effect of bisphosphonate hydrogel toward osteoclast activity and relapse movement. Saudi Dent J. 2021; 33(5): 292-8. DOI: 10.1016/j.sdentj.2020.03.003.

Parlina C, Purwaningsih EH, Jusuf AA, Widayati R. Impact of Zoledronate Bisphosphonate Gel in Virgin Coconut Oil on the Increase of Osteoclast Apoptosis. Int J App Pharm. 2017; 9(Special issue 2):24. DOI: 10.22159/ijap.2017.v9s2.07

Ajazuddin, Alexander A, Khichariya A, Gupta S, Patel RJ, Giri TK, et al. Recent expansions in an emergent novel drug delivery technology: Emulgel. J Control Release. 2013; 171(2): 122-32. DOI: 10.1016/J.JCONREL.2013.06.030

Chirag J P, Tyagi S, Gupta AK, Sharma P, Prajapati PM, Potdar MB. Emulgel: A Combination of Emulsion and Gel. 2013;1(6):5.

Boddupalli B, Mohammed Zulkar NK, Nath R, Banji D. Mucoadhesive Drug Delivery System: An Overview. J Adv Pharm Tech Res. 2012; 1(4): 381. DOI: 10.4103/0110-5558.76436.

Bhowmik D, Gopinath H, Kumar BP, Duraivel S, Kumar KPS. Controlled Release Drug Delivery Systems. The Pharma Innovation. 2012; 1(10): 9.

Patel J, Patel A. Artificial Neural Networking in Controlled Drug Delivery. In: Artificial Neural Network for Drug Design, Delivery and Disposition. Elsevier; 2016. p. 195–218.

Saito T, Tabata Y. Preparation of gelatin hydrogels incorporating low-molecular-weight heparin for anti-fibrotic therapy. Acta Biomater. 2012; 8(2): 646-52. DOI: 10.1016/j.actbio.2011.10.025.

Swami AS, Pishawikar SA, More HN. Development and Validation of Stability Indicating UV Spectrophotometric Method for the Estimation of Sodium Risedronate. International Journal of Pharmacy and Pharmaceutical Sciences. 2012; 4(3): 4.

Saputra AH, Qadhayna L, Pitaloka AB. Synthesis and Characterization of Carboxymethyl Cellulose (CMC) from Water Hyacinth Using Ethanol-Isobutyl Alcohol Mixture as the Solvents. IJCEA. 2014;5(1):36–40.

Kuentz M, Holm R, Elder DP. Methodology of oral formulation selection in the pharmaceutical industry. Eur J Pharm Sci. 2016; 87: 136-63. DOI: 10.1016/J.EJPS.2015.12.008

Yun YH, Lee BK, Park K. Controlled drug delivery: Historical perspective for the next generation. J Control Release. 2015; 219: 2-7. DOI: 10.1016/J.JCONREL.2015.10.005

Nokhodochi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablet in drug delivery systems. BioImpacts. 2012; 2(4): 175–87. DOI: 10.5681/bi.2012.027

Berdey II, Voyt OI. Rheological Properties of Emulgel Formulations Based on Different Gelling Agent. 2016;4.

Lim YW, Tan WS, Ho KL, Mariatulqabtiah AR, Abu Kasim NH, Abd. Rahman N, et al. Challenges and complications of poly(lactic-co-glycolic acid)-based long-acting drug product development. Pharmaceutics. 2022; 14(3): 614. DOI: 10.3390/PHARMACEUTICS14030614

Shelke O, Kulkarni A. Formulation, Development and Evaluation of Nifedipine Emulgel for Treatment of Anal Fissures Using Polymeric Emulsifiers. IJPER. 2019; 53(2s): s74–81. DOI: 10.5530/ijper.53.2s.51

Shelke O, Sharma M. Development of Sustained Release Hydrophobic Emulgel for Oral Care. Journal of Drug Delivery. 2019; 9(3): 8. DOI: 10.22270/jddt.v9i3.2702

Wakhet S, Singh VK, Sahoo S, Sagiri SS, Kulanthaivel S, Bhattacharya MK, Kumar N, Banerjee I, Pal K. Characterization of gelatin-agar based phase separated hydrogel, emulgel and bigel: a comparative study. J Mater Sci Mater Med. 2015; 26(2): 118. DOI: 10.1007/s10856-015-5434-2.

Altaani BM, Almaaytah AM, Dadou S, Alkhamis K, Daradka MH, Hananeh W. Oral Delivery of Teriparatide Using a Nanoemulsion System: Design, in Vitro and in Vivo Evaluation. Pharm Res. 2020; 37(4): 80. DOI: 10.1007/s11095-020-02793-0.

Fazil M, Hassan MQ, Baboota S, Ali J. Biodegradable Intranasal Nanoparticulate Drug Delivery System of Risedronate Sodium for Osteoporosis. Drug Delivery. 2015; 1–11. DOI: 10.3109/10717544.2014.1002947.

Kute SB, Saudagar RB. Emulsified Gel A Novel Approach for Delivery of Hydrophobic Drugs: An Overview. 2013;3(4):9.

Kurniawan DW, Fudholi A, Susidarti RA. Synthesis of thiolated chitosan as matrix for the preparation of metformin hydrochloride microparticles. Res Pharm. 2012; 2(1): 26-35.

Mahato RI, Narang AS. Pharmaceutical Dosage Forms and Drugs Delivery. 2nd Ed. Boca Raton: CRC Press; 2012.11 p.

Vats S, Saxena C, Easwari T, Shukla V. Emulsion Based Gel Technique: Novel Approach for Enhancing Topical Drug Delivery of Hydrophobic Drugs. International Journal for Pharmaceutical Research Scholars (IJPRS). 2014; 3(2): 13.

Preeti B, Gnanaranjan G. Emulgels: A Novel Formulation Approach for Topical Delivery of Hydrophobic Drugs. Int Res J Pharmacy. 2013; 4(2): 5.

Andrade GM de, Ribeiro CC, Plank BCA. Pharmaceutical Equivalence and Comparative Dissolution Profile Studies for Coated Tablets Containing Verapamil Hydrochloride. 2018;16.

Kazancioglu HO, Aksakalli S, Ezirganli S, Birlik M, Esrefoglu M, Acar AH. Effect of Caffeic Acid Phenethyl Ester on Bone Formation in the Expanded Inter-Premaxillary Suture. Drug Des Devel Ther. 2015; 9: 6483–6488. DOI: 10.2147/DDDT.S97797

Proffit W. Contemporary Orthodontics. 6th Ed. Philadelphia; 2018. 744p.

Cobourne MT, DiBiase AT. Handbook of Orthodontics. 2nd Ed. Edinburgh; New York: Mosby; 2015. 584 p.

DOI: https://doi.org/10.24198/pjd.vol34no1.32628